Disclosed herein are recombinant viruses and/or insect cells suitable for detecting the infection of a pathogen in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the pathogen or not, so that proper course of treatment may be assigned to the subject. Also disclosed herein is a vaccine for the prophylaxis and/or treatment of infection caused by said pathogen.

A method for producing a recombinant adeno-associated virus (rAAV) and a recombinant baculovirus virus, the method including: (1) infecting an insect host packaging cell line with a corresponding recombinant baculovirus integrated with an rAAV genome ITR-GOI (gene of interest flanked by AAV inverted terminal repeats) and an AAV Cap gene or AAV Rep gene; (2) culturing the host packaging cell line infected with the recombinant baculovirus, so as to produce the recombinant adeno-associated virus; and (3) separating and purifying the recombinant adeno-associated virus obtained in (2).

The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.

A method of easily producing an immunogenic pupa for oral administration and a pupa for oral administration produced by the method are provided. The method is a method of producing a pupa for oral administration, including a step of infecting a larva or pupa of an insect capable of being baculovirus-infected with a recombinant baculovirus having DNA encoding an antigen protein introduced therein and freeze-drying a pupa having pupated from the infected larva or the infected pupa.

The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.

The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.

gp64 is the major envelope glycoprotein of baculoviruses. The present invention relates to novel proteins that specifically bind to the baculovirus envelope protein gp64. The novel proteins of the present invention are advanced and powerful tools because they allow precise capturing of gp64 in affinity chromatography. The gp64 binding proteins are particularly useful tools within the process of protein production (e.g. vaccine production) to provide for gp64 free samples. Further, the binding protein for gp64 are useful for methods to analyze the presence of gp64.

The present disclosure provides a novel genetically modified high productivity VVK-V432C insect cell line derived from the ATCC CRL-1711 cell line. Methods for obtaining this high productivity cell line are also provided.

A method for producing a recombinant adeno-associated virus (rAAV) and a recombinant baculovirus virus, the method including: (1) infecting an insect host packaging cell line with a corresponding recombinant baculovirus integrated with an rAAV genome ITR-GOI (gene of interest flanked by AAV inverted terminal repeats) and an AAV Cap gene or AAV Rep gene; (2) culturing the host packaging cell line infected with the recombinant baculovirus, so as to produce the recombinant adeno-associated virus; and (3) separating and purifying the recombinant adeno-associated virus obtained in (2).

A method for increasing or enhancing baculovirus yield and/or recombinant protein expression from a baculovirus is provided, wherein said method includes the step of engineering said host cell to express one or more of a p35, p35-trunc, p35-trunc-tail, and p49 protein. In some embodiments, said baculovirus does not normally encode a p35 protein, and said method includes the step of engineering said host cell to express one or more of a p35, p35-trunc, and p35-trunc-tail protein. In some embodiments, said baculovirus does not normally encode a p49 protein, and said method includes the step of engineering said host cell to express a p49 protein. Also provided are isolated p35-trunc and p35-trunc-tail proteins.